

MID AND SOUTH ESSEX MEDICINES OPTIMISATION COMMITTEE (MSEMOC)

DUPIBUMAB FOR TREATING CHRONIC RHINOSINUSITIS WITH NASAL POLYPS, NICE TA648, SEPTEMBER 2020 (TERMINATED APPRAISAL)

**BLACK: NOT RECOMMENDED FOR PRESCRIBING IN PRIMARY, COMMUNITY OR
SECONDARY CARE**

Mid and South Essex CCGs do not support the prescribing of dupilumab for treating chronic rhinosinusitis with nasal polyps in accordance with local recommendations for all drugs with a terminated NICE technology appraisal.

[NICE TA648](#) guidance:

NICE is unable to make a recommendation on dupilumab (Dupixent®) for treating chronic rhinosinusitis with nasal polyps because Sanofi did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.

Providers commissioned to provide services on behalf of Mid and South Essex CCGs are reminded that they are required to follow the local joint formulary and prescribing guidance, as detailed in the medicines management service specification of their contract.

References	NICE TA648: Dupilumab for treating chronic rhinosinusitis with nasal polyps: https://www.nice.org.uk/guidance/ta648
Acknowledgements	Mid and South Essex CCGs Medicines Management Teams
Version	1.0
Author	HCPMSEMOC working group
Approved by	Mid and South Essex Medicines Optimisation Committee (MSEMOC); Mid and South Essex Joint Committee
Date Approved	October 2020; November 2020
Review Date	October 2025 or sooner if subject to any new updates nationally